Prognostic and Treatment Characteristics of Metastatic KRAS G12C Mutant NSCLC

被引：0
|
作者：
Elegbede, A. [1 ]
Ezeife, D. [2 ]
Gibson, A. [1 ]
Dean, M. [1 ]
Petersen, L. [1 ]
Bebb, G. [1 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Brain metastasis; Gender; KRAS mutant NSCLC survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P59.25
引用
收藏
页码：S1159 / S1160
页数：3
相关论文
共 50 条
  • [31] The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study
    Chida, Keigo
    Kotani, Daisuke
    Masuishi, Toshiki
    Kawakami, Takeshi
    Kawamoto, Yasuyuki
    Kato, Kyoko
    Fushiki, Kunihiro
    Sawada, Kentaro
    Kumanishi, Ryosuke
    Shirasu, Hiromichi
    Matsubara, Yuki
    Yuki, Satoshi
    Komatsu, Yoshito
    Yamazaki, Kentaro
    Yoshino, Takayuki
    ONCOLOGIST, 2021, 26 (10): : 845 - 853
  • [32] The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C
    Notario Rincon, L.
    Pous, A.
    Lopez-Paradis, A.
    Cerda, G.
    Cucurull, M.
    Hernandez, A.
    Domenech, M.
    Carcereny, E.
    Moran Bueno, M. T.
    Munoz, A.
    Mate, J. L.
    Sanz, C.
    Saigi, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S50 - S50
  • [33] Association of KRAS G12C Status with Age at Onset of Metastatic Colorectal Cancer
    Aruquipa, Marcelo Sunagua
    Peixoto, Renata D'Alpino
    Jacome, Alexandre
    Cesar, Fernanda
    Lorandi, Vinicius
    Dienstmann, Rodrigo
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2024, 46 (02) : 1374 - 1382
  • [34] KRAS G12C inhibitors in metastatic colorectal cancer: a tale of two targets
    Martinez-Perez, Julia
    Valladares-Ayerbes, Manuel
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 9
  • [35] Prognostic implication of KRAS G12C mutation in a real-world KRAS mutated stage IV NSCLC cohort treated with immunotherapy in the Netherlands
    Noordhof, Anneloes L.
    Swart, Esther M.
    Damhuis, Ronald A. M.
    Hendriks, Lizza E. L.
    Kunst, Peter W. A.
    Aarts, Mieke J.
    Van Geffen, Wouter H.
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62
  • [36] Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report
    Barot, Hasti
    Evans, Joanne
    Mohammed, Waleed
    Power, Danielle
    LUNG CANCER, 2022, 165 : S77 - S77
  • [37] Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
    Choi, Yoonha
    Dharia, Neekesh V.
    Jun, Tomi
    Chang, Julie
    Royer-Joo, Stephanie
    Yau, Kenneth K.
    Assaf, Zoe J.
    Aimi, Junko
    Sivakumar, Smruthy
    Montesion, Meagan
    Sacher, Adrian
    LoRusso, Patricia
    Desai, Jayesh
    Schutzman, Jennifer L.
    Shi, Zhen
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3788 - 3797
  • [38] KO-2806, a next-generation farnesyl transferase inhibitor, re-sensitizes KRAS G12C NSCLC tumors to KRAS G12C mutant-specific inhibitors through mTOR signaling inhibition
    Patel, H.
    Chan, S.
    Smith, A.
    Burrows, F.
    Malik, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S146 - S146
  • [39] KRAS G12C mutation is not undruggable anymore
    Rodrigues, Manuel
    BULLETIN DU CANCER, 2020, 107 (02) : 145 - 145
  • [40] Targeting KRAS G12C with Covalent Inhibitors
    Ostrem, Jonathan M. L.
    Shokat, Kevan M.
    ANNUAL REVIEW OF CANCER BIOLOGY, 2022, 6 : 49 - 64
12345